Oral flurbiprofen metabolic ratio assessment using a single-point dried blood spot

Clinical Pharmacology and Therapeutics

Volumn 91, Issue 3, 2012, Pages 489-496

  Daali, Y ^a,b   Samer, C ^a,b   Deglon J ^b,c   Thomas, A ^a,b   Chabert, J ^a   Rebsamen, M ^a   Staub, C ^b,c   Dayer, P ^a,b   Desmeules, J ^a,b  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b UNIVERSITY OF GENEVA   (Switzerland)

^c UNIVERSITY CENTER OF LEGAL MEDICINE   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

FLUCONAZOLE; FLURBIPROFEN; RIFAMPICIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; DRIED BLOOD SPOT TESTING; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG METABOLISM; HUMAN; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; PRIORITY JOURNAL; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADMINISTRATION, ORAL; ADULT; AREA UNDER CURVE; ARYL HYDROCARBON HYDROXYLASES; DRIED BLOOD SPOT TESTING; FLUCONAZOLE; FLURBIPROFEN; GENOTYPE; HUMANS; HYDROLYSIS; MALE; RIFAMPIN; YOUNG ADULT;

EID: 84857239768     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2011.247     Document Type: Article

References (31)

1. Dlon, J., Lauer, E., Thomas, A., Mangin, P. & Staub, C. Use of the dried blood spot sampling process coupled with fast gas chromatography and negativeion chemical ionization tandem mass spectrometry: application to fluoxetine, norfluoxetine, reboxetine, and paroxetine analysis. Anal. Bioanal. Chem. 396, 2523-2532 (2010).
2. Boer, T. et al. Application of dried blood spot sampling combined with LC-MS/MS for genotyping and phenotyping of CYP450 enzymes in healthy volunteers. Biomed. Chromatogr. 25, 1112-1123 (2011).
3. Patel, P., Mulla, H., Tanna, S. & Pandya, H. Facilitating pharmacokinetic studies in children: a new use of dried blood spots. Arch. Dis. Child. 95, 484-487 (2010).
4. Edelbroek, P.M., van der Heijden, J. & Stolk, L.M. Dried blood spot methods in therapeutic drug monitoring: methods, assays, and pitfalls. Ther. Drug Monit. 31, 327-336 (2009).
5. Thomas, A., Dlon, J., Steimer, T., Mangin, P., Daali, Y. & Staub, C. On-line desorption of dried blood spots coupled to hydrophilic interaction/reversedphase LC/MS/MS system for the simultaneous analysis of drugs and their polar metabolites. J. Sep. Sci. 33, 873-879 (2010).
6. Li, W. & Tse, F.L. Dried blood spot sampling in combination with LC-MS/MS for quantitative analysis of small molecules. Biomed. Chromatogr. 24, 49-65 (2010).
7. Lee, C.R., Pieper, J.A., Frye, R.F., Hinderliter, A.L., Blaisdell, J.A. & Goldstein, J.A. Tolbutamide, flurbiprofen, and losartan as probes of CYP2C9 activity in humans. J. Clin. Pharmacol. 43, 84-91 (2003). (Pubitemid 36015447)
8. Streetman, D.S., Bertino, J.S. Jr & Nafziger, A.N. Phenotyping of drugmetabolizing enzymes in adults: a review of in-vivo cytochrome P450 phenotyping probes. Pharmacogenetics 10, 187-216 (2000). (Pubitemid 30242736)
9. Jetter, A. et al. Cytochrome P450 2C9 phenotyping using low-dose tolbutamide. Eur. J. Clin. Pharmacol. 60, 165-171 (2004). (Pubitemid 38757127)
10. Caraco, Y., Muszkat, M. & Wood, A.J. Phenytoin metabolic ratio: a putative marker of CYP2C9 activity in vivo. Pharmacogenetics 11, 587-596 (2001). (Pubitemid 32953584)
11. Dumond, J.B. et al. A phenotype-genotype approach to predicting CYP450 and P-glycoprotein drug interactions with the mixed inhibitor/inducer tipranavir/ritonavir. Clin. Pharmacol. Ther. 87, 735-742 (2010).
12. Christensen, M. et al. The Karolinska cocktail for phenotyping of five human cytochrome P450 enzymes. Clin. Pharmacol. Ther. 73, 517-528 (2003). (Pubitemid 37249122)
13. Zgheib, N.K., Frye, R.F., Tracy, T.S., Romkes, M. & Branch, R.A. Evaluation of flurbiprofen urinary ratios as in vivo indices for CYP2C9 activity. Br. J. Clin. Pharmacol. 63, 477-487 (2007). (Pubitemid 46426631)
14. Tracy, T.S., Marra, C., Wrighton, S.A., Gonzalez, F.J. & Korzekwa, K.R. Studies of flurbiprofen 4'-hydroxylation. Additional evidence suggesting the sole involvement of cytochrome P450 2C9. Biochem. Pharmacol. 52, 1305-1309 (1996). (Pubitemid 26355306)
15. Jerdi, M.C., Daali, Y., Oestreicher, M.K., Cherkaoui, S. & Dayer, P. A simplified analytical method for a phenotyping cocktail of major CYP450 biotransformation routes. J. Pharm. Biomed. Anal. 35, 1203-1212 (2004). (Pubitemid 39140285)
16. Cheung, C.Y. et al. Dried blood spot measurement: application in tacrolimus monitoring using limited sampling strategy and abbreviated AUC estimation. Transpl. Int. 21, 140-145 (2008).
17. Emmons, G. & Rowland, M. Pharmacokinetic considerations as to when to use dried blood spot sampling. Bioanalysis 2, 1791-1796 (2010).
18. Daali, Y., Cherkaoui, S., Doffey-Lazeyras, F., Dayer, P. & Desmeules, J.A. Development and validation of a chemical hydrolysis method for dextromethorphan and dextrophan determination in urine samples: application to the assessment of CYP2D6 activity in fibromyalgia patients. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 861, 56-63 (2008). (Pubitemid 50009267)
19. Rowland, M. & Emmons, G.T. Use of dried blood spots in drug development: pharmacokinetic considerations. AAPS J. 12, 290-293 (2010).
20. Mano, Y., Usui, T. & Kamimura, H. Predominant contribution of UDPglucuronosyltransferase 2B7 in the glucuronidation of racemic flurbiprofen in the human liver. Drug Metab. Dispos. 35, 1182-1187 (2007). (Pubitemid 46956440)
21. Mano, N., Narui, T., Nikaido, A. & Goto, J. Separation and determination of diastereomeric flurbiprofen acyl glucuronides in human urine by LC/ESI-MS with a simple column-switching technique. Drug Metab. Pharmacokinet. 17, 142-149 (2002).
22. Davies, N.M. Clinical pharmacokinetics of flurbiprofen and its enantiomers. Clin. Pharmacokinet. 28, 100-114 (1995).
23. Lee, C.R., Pieper, J.A., Frye, R.F., Hinderliter, A.L., Blaisdell, J.A. & Goldstein, J.A. Differences in flurbiprofen pharmacokinetics between CYP2C9*1/*1, *1/*2, and *1/*3 genotypes. Eur. J. Clin. Pharmacol. 58, 791-794 (2003). (Pubitemid 36577808)
24. Patel, B.K., Jackson, S.H., Swift, C.G. & Hutt, A.J. Disposition of flurbiprofen in man: influence of stereochemistry and age. Xenobiotica. 33, 1043-1057 (2003). (Pubitemid 37346686)
25. Vormfelde, S.V. et al. Relative impact of genotype and enzyme induction on the metabolic capacity of CYP2C9 in healthy volunteers. Clin. Pharmacol. Ther. 86, 54-61 (2009).
26. Kanebratt, K.P. et al. Cytochrome P450 induction by rifampicin in healthy subjects: determination using the Karolinska cocktail and the endogenous CYP3A4 marker 4beta-hydroxycholesterol. Clin. Pharmacol. Ther. 84, 589-594 (2008).
27. Lee, K.H. et al. Time course of the changes in prednisolone pharmacokinetics after co-administration or discontinuation of rifampin. Eur. J. Clin. Pharmacol. 45, 287-289 (1993). (Pubitemid 23290383)
28. Tran, J.Q., Kovacs, S.J., McIntosh, T.S., Davis, H.M. & Martin, D.E. Morning spot and 24-hour urinary 6 beta-hydroxycortisol to cortisol ratios: intraindividual variability and correlation under basal conditions and conditions of CYP 3A4 induction. J. Clin. Pharmacol. 39, 487-494 (1999). (Pubitemid 29356469)
29. Hutzler, J.M., Frye, R.F. & Tracy, T.S. Sensitive and specific high-performance liquid chromatographic assay for 4'-hydroxyflurbiprofen and flurbiprofen in human urine and plasma. J. Chromatogr. B. Biomed. Sci. Appl. 749, 119-125 (2000).
30. Deglon, J. et al. Automated system for on-line desorption of dried blood spots applied to LC/MS/MS pharmacokinetic study of flurbiprofen and its metabolite. J. Pharm. Biomed. Anal. 54, 359-367 (2011).
31. Thomas, A. et al. High-throughput phospholipidic fingerprinting by online desorption of dried spots and quadrupole-linear ion trap mass spectrometry: evaluation of atherosclerosis biomarkers in mouse plasma. Anal. Chem. 82, 6687-6694 (2010).